Company Description
Santarus targets more than a little tummy ache. The company's flagship drug Zegerid is a modified version of omeprazole, the proton pump inhibitor...
Key Santarus Financials
| Company Type | Public - NASDAQ (GM): SNTS Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $94.4 |
| 2005 Employees | 328 |
More Santarus Financials (11 pages)
Competition
Competitive Landscape for Pharmaceutical Manufacture and Sale
The industry is marked by rapid advances in scientific knowledge that produce ever-more effective medicines. Profitability is determined mainly by the ability to discover new drugs. The industry is...
Read more about Santarus's competition across multiple industries
Top Santarus Competitors
Sponsored Links
The Business Directory
Santarus Executives
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman | David F. Hale | Network | E-mail |
| President, CEO, and Director | Gerald T. Proehl | Network | E-mail |
| SVP, CFO, Treasurer, and Secretary | Debra P. Crawford | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current Santarus News
- FirstAlert: 3-3:50 P.M. Investrend / Bestcalls [InvesTrend] (03 Sep 2008 00:01:00 EDT)
- Depomed Reports Second Quarter 2008 Financial Results [Diabetes Week] (18 Aug 2008 00:01:00 EDT)
Sponsored Opportunity
